Executive CI Snapshot
Geographic atrophy is moving into its second competitive wave, in which commercial success is no longer driven by being first-in-class but rather by providing functional vision protection, safety assurance, reduced treatment burden, and payer/regulatory approval. Syfovre and Izervay currently represent the only two approved options in the United States for GA as a complication of AMD, yet this area is rapidly evolving, with approved complement inhibitors under threat from oral medicines, neuroprotective agents, gene therapy, and even regenerative cellular therapies.
GA is not just an opportunity in the retinal disease pipeline anymore, but it is becoming a commercial and evidence-generating competition. The Biogen’s acquisition of Apellis has increased the commercial firepower of Syfovre as they have increased their scale in accessing the market and engaging physicians. Syfovre had revenues of $587 million in net product sales in 2025 in the U.S. while maintaining 60% GA market share.
On the other hand, Astellas is enhancing the competitiveness of Izervay through extended U.S. prescribing information, which facilitates prolonged therapy usage beyond the prior restriction, in addition to further evidence accumulation and expansion of the drug across the U.S., Australia, Macau and conditional approval in Japan. The upcoming GA competition will be determined by the resources that would minimize injection burden, achieve better visual results for patients or provide a different mechanism of action, such as oral formulation, systemic complement inhibition, gene therapy and cell therapies.
Disease Overview:
Geographic atrophy (GA) is a late-stage form of dry age-related macular degeneration characterized by progressive loss of retinal pigment epithelium, photoreceptors and supporting macular tissues, leading to irreversible central vision decline. Although lesion growth is a key clinical marker, disease impact is closely linked to functional vision loss, including reduced reading ability, low-light vision and central vision independence. GA often progresses slowly but may affect both eyes, increasing patient dependency and the need for regular monitoring. Disease management typically requires retinal imaging, long-term follow-up and specialist-led care, making treatment frequency, safety and ease of care important considerations.
Epidemiology Analysis
Geographic atrophy (GA), an advanced form of age-related macular degeneration, affects approximately 5 million people globally and 1 million in the United States. Its prevalence increases sharply with age, particularly in individuals over 75 years old.
Approved Drugs
As of May 2026, the geographic atrophy treatment market is led by two FDA-approved drugs: Syfovre (pegcetacoplan), and Izervay (avacincaptad pegol). Syfovre, now under Biogen, targets complement C3, while Izervay, marketed by Astellas, targets complement C5. Both therapies are delivered through intravitreal injection and are used to slow GA lesion growth in patients with dry AMD.
In FY2025, Syfovre recorded sales revenue of around USD 587 million, while Izervay generated sales revenue of approximately USD 514 million. Sales growth is expected to remain positive, supported by improved diagnosis, longer treatment duration, physician familiarity and broader market access. However, frequent injections, safety monitoring and the need for stronger functional vision outcomes may limit faster adoption.
Pipeline Analysis
As of May 2026, the therapeutic pipeline for geographic atrophy (GA) is robust, encompassing various modalities aimed at slowing disease progression and preserving vision. Here's an overview of key investigational therapies across different classes:
| Sponsor | Intervention | Current Status | MoA | RoA | Modality |
| Regeneron | Cemdisiran alone or cemdisiran plus pozelimab | Phase III | C5 suppression through siRNA and antibody combination | Subcutaneous | siRNA plus monoclonal antibody |
| Annexon | Vonaprument, formerly ANX007 | Phase III | C1q inhibition | Intravitreal | Antibody fragment |
| Belite Bio | Tinlarebant | Phase III | RBP4 antagonist, visual-cycle modulation | Oral | Small molecule |
Stealth Bio Therapeutics | Elamipretide | Phase III | Mitochondrial dysfunction modulation | Subcutaneous | Peptide |
| Aviceda Therapeutics | AVD-104 | Phase IIb completed; Phase III planning | Siglec-mediated immune modulation and macrophage repolarization | Intravitreal | Sialic acid-coated nanoparticle |
| Ocugen | OCU410 | Phase I/II | RORA modifier gene therapy | Subretinal | Gene therapy |
Alkeus Pharmaceuticals | Gildeuretinol acetate (ALK-001) | Completed Phase II/III | Reduces vitamin A dimerization without modulating the visual cycle | Oral | Small molecule |
| Johnson & Johnson | JNJ-81201887 (JNJ-1887) | Phase II | Soluble CD59 expression to inhibit MAC formation | Intravitreal | Gene therapy |
Roche / Genentech / Lineage | OpRegen (RG6501) | Phase II | RPE cell replacement | Subretinal | Cell therapy |
| Boehringer Ingelheim | BI 1584862 | Phase II | Phospholipid modulation | Oral | Small molecule |
Boehringer Ingelheim/ CDR-Life | BI 771716 | Phase II | GA-targeted antibody fragment | Intravitreal | Antibody fragment |
Alexion Pharmaceuticals Inc. | Danicopan | Phase II dose-finding | Complement factor D inhibition | Oral | Small molecule |
| ADARx Pharmaceuticals | Agazisiran (ADX-038) | Phase II | Complement factor B silencing | Subcutaneous | siRNA |
| ONL Therapeutics | Xelafaslatide (formerly ONL1204) | Phase II | Fas pathway inhibition | Intravitreal | Peptide / small molecule |
| Galimedix Therapeutics | GAL-101 | Phase II | Amyloid beta aggregation modulation | Topical eye drops | Small molecule |
| Kriya Therapeutics | KRIYA-825 (VV-14295) | Phase I/II | AAV-CR2-CR1 complement C3 and C5 inhibition | Suprachoroidal | Gene therapy |
| Eyestem Research | Eyecyte-RPE | Phase II approved / ongoing in India | RPE cell replacement | Subretinal | Cell therapy |
| Luxa Biotechnology | RPESC-RPE-4W | Phase I/IIa | RPE stem-cell replacement | Subretinal | Cell therapy |
| Cognition Therapeutics | Zervimesine (CT1812) | Phase II completed | Sigma-2 receptor modulation / RPE protection | Oral | Small molecule |
| BioJiva | BRX011 | Phase I/II | Oxidative stress and retinal degeneration modulation | Oral | Small molecule |
| Nanoscope Therapeutics | MCO-010 | Phase II GA program expected in late 2026 | Optogenetic vision restoration | Intravitreal | Gene therapy |
Market Size & Forecasting
The Global Geographic Atrophy (GA) Market stood at US$ 22.7 billion in 2025 and is expected to reach US$ 44.59 billion by 2035, growing with a CAGR of 7.2% during the forecast period 2026-2035.
Competitive Landscape and Market Positioning
The current GA market is led by Syfovre and Izervay, but faces growing competition from diversified Phase III pipelines. Regeneron’s pozelimab is the most immediate threat due to its similar mechanism and corporate muscle, while oral therapies like Tinlarebant and Gildeuretinol could shift patient preference toward non-invasive treatments. Novel mechanisms (e.g., ANX007, AVD-104, cell therapy, and gene therapy) add depth and may reshape long-term market dynamics.
| Company | Drug | Stage | Mechanism | Delivery | Key Differentiator | Competitive Position |
Apellis (acquired by Biogen) | Syfovre (pegcetacoplan) | Approved (US) | C3 inhibitor | Intravitreal | First-to-market, broad complement inhibition | First FDA-approved drug with early advantage; under safety watch |
| Astellas | Izervay (avacincaptad pegol) | Approved (US); Pre-registration (Japan) | C5 inhibitor | Intravitreal | Safer C5 targeting; global expansion planned | Strong competitor to Syfovre |
| Regeneron | Pozelimab | Phase III | C5 inhibitor | Intravitreal | Leverages Regeneron’s strong retina franchise | High threat due to scale and experience |
| Belite Bio | Tinlarebant | Phase III | RBP4 inhibitor (vitamin A pathway) | Oral | Non-invasive, daily oral tablet | Moderate threat; ideal for patients avoiding injections |
| Annexon | ANX007 | Phase III | C1q inhibitor | Intravitreal | Neuroprotective and anti-inflammatory | Unique MOA; appealing for early intervention |
| Alkeus | Gildeuretinol | Phase III | Deuterated vitamin A analog | Oral | Targets retinal stress; oral administration | Moderate potential with systemic delivery |
| Aviceda | AVD-104 | Phase II/III | Siglec-targeted nanoparticle | Intravitreal | Immunomodulatory + anti-inflammatory action | Differentiated MOA; in early pivotal testing |
Roche / Genentech / Lineage | OpRegen (RG6501) | Phase II | RPE cell replacement therapy | Subretinal | Regenerative cell therapy approach | Long-term potential; invasive delivery limits scale |
| Johnson & Johnson | JNJ-81201887 (JNJ-1887) | Phase II | AAV-sCD59 gene therapy | Intravitreal | Sustained complement inhibition via gene delivery | Early gene therapy with durable effect potential |
Summary Insights
- The market is evolving from complement inhibitors to oral, regenerative, and gene-based approaches.
- Syfovre and Izervay dominate for now, but face growing pressure from:
- Convenience-focused oral drugs (Tinlarebant, Gildeuretinol)
- Differentiated MOA candidates (ANX007, AVD-104)
- Transformative platforms like cell therapy (OpRegen) and gene therapy (JNJ-1887).
Key Companies:
Target Opportunity Profile (TOP)
To compete effectively against approved drugs like Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) in the geographic atrophy (GA) market, emerging therapies must demonstrate a superior Target Opportunity Profile (TOP) across several critical dimensions.
Target Opportunity Profile (TOP) – Competitive Attributes
| Dimension | Desired Profile for Emerging Therapies | Rationale |
| Safety |
| Safety concerns (esp. with Syfovre) remain a barrier to uptake and long-term adherence |
| Efficacy |
| Approved drugs slow lesion progression but do not improve vision |
Mechanism of Action (MOA) |
| Innovative MOAs may address non-responders and expand treatment to broader populations |
Route of Administration (ROA) |
| Monthly/bi-monthly intravitreal injections are burdensome and limit compliance |
| Dosing Frequency |
| Reduces clinic visits, enhances real-world feasibility |
| Modality |
| Disruptive modalities can enable disease-modifying or one-time treatments |
| Durability |
| Addresses chronic nature of GA while reducing treatment burden |
| Innovation Level |
| Payers and physicians favor drugs with clear mechanistic differentiation |
Visual Function Impact |
| Current approvals focus only on anatomical (lesion) slowing; functional endpoints are unmet |
Patient Population Targeting |
| May capture untreated segments where current therapies are not yet approved |
Unmet Needs & Market Dynamics
Geographic atrophy presents a high unmet need as current therapies slow lesion growth but do not restore lost vision or consistently demonstrate strong functional vision benefits. The market is evolving around earlier diagnosis, long-term retinal monitoring, treatment burden reduction, safety confidence and the need for therapies that better preserve daily visual function.
Strategic Summary
Emerging therapies in geographic atrophy will need to deliver a clear advantage over Syfovre and Izervay to gain meaningful market share. Lesion-growth reduction alone may not be sufficient. Future products must demonstrate stronger patient-relevant outcomes, including preservation of reading ability, low-light vision, contrast sensitivity and central vision function.
Safety will remain a key adoption driver, particularly due to concerns around intraocular inflammation, wet AMD conversion and the need for long-term monitoring. Therapies that reduce treatment burden through oral dosing, longer dosing intervals, subcutaneous delivery, gene therapy or cell-based approaches are likely to have stronger real-world uptake.
Differentiated mechanisms such as C1q inhibition, RBP4 modulation, complement silencing, mitochondrial protection and retinal cell replacement may expand treatment options across broader GA patient groups. Overall, market success will depend on a balanced profile combining efficacy, functional vision protection, safety, convenience and clear clinical differentiation.
Why Buy Our Geographic Atrophy (GA) Competitive Intelligence Report?
The geographic atrophy market is entering a new competitive phase, driven by the launch of approved complement inhibitors, expanding late-stage pipelines and growing demand for therapies that preserve functional vision. As treatment decisions become more complex, companies need clear intelligence on clinical differentiation, safety, patient selection, access dynamics and future pipeline disruption. Our report helps clients convert this evolving ophthalmology landscape into actionable commercial and clinical strategies.
Identify where competition is intensifying
Understand how approved therapies such as Syfovre and Izervay are shaping the current market, which companies are advancing differentiated pipeline assets and which mechanisms may define the next treatment wave.
Prioritize the right patient segments
Assess commercially relevant GA patient pools, including diagnosed patients, treatment-eligible patients, bilateral GA, foveal and non-foveal disease, and patients at risk of functional vision decline.
Evaluate asset differentiation
Compare therapies based on lesion-growth reduction, functional vision preservation, safety profile, dosing frequency, route of administration, durability and fit within retina-specialist workflows.
Track regulatory and launch readiness
Monitor approval timelines, clinical trial readouts, label expansion opportunities, geographic access developments and commercialization readiness across approved and investigational therapies.
Support pricing and access planning
Understand payer expectations, reimbursement barriers, treatment eligibility criteria, injection burden and evidence requirements that may influence adoption across key markets.
Strengthen business development decisions
Identify attractive licensing, partnership, acquisition and investment opportunities across complement inhibitors, oral therapies, gene therapies, cell therapies and other emerging GA treatment platforms.
